Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tysabri natalizumab: Additional Phase III data

Researchers published in the Annals of Neurology additional data from the previously reported 2-year, double-blind, placebo-controlled, international Phase III AFFIRM trial. The

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE